FY2025 EPS Estimates for TScan Therapeutics Cut by Wedbush

TScan Therapeutics, Inc. (NASDAQ:TCRXFree Report) – Research analysts at Wedbush reduced their FY2025 earnings per share estimates for shares of TScan Therapeutics in a report released on Wednesday, March 5th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.98) per share for the year, down from their previous forecast of ($0.97). Wedbush currently has a “Outperform” rating and a $7.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. Wedbush also issued estimates for TScan Therapeutics’ Q4 2025 earnings at ($0.22) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.96) EPS and FY2028 earnings at ($0.89) EPS.

TScan Therapeutics (NASDAQ:TCRXGet Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The company had revenue of $0.67 million for the quarter, compared to analyst estimates of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%.

A number of other research firms have also recently issued reports on TCRX. Barclays cut their price objective on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research report on Friday. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a report on Thursday. Finally, Needham & Company LLC decreased their price objective on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, TScan Therapeutics has a consensus rating of “Buy” and an average price target of $9.20.

Check Out Our Latest Analysis on TScan Therapeutics

TScan Therapeutics Stock Down 4.8 %

Shares of NASDAQ TCRX opened at $1.98 on Monday. TScan Therapeutics has a 12-month low of $1.82 and a 12-month high of $9.69. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. The firm has a market cap of $105.67 million, a PE ratio of -1.87 and a beta of 0.91. The company’s fifty day simple moving average is $2.41 and its 200 day simple moving average is $3.99.

Hedge Funds Weigh In On TScan Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Heck Capital Advisors LLC bought a new position in shares of TScan Therapeutics in the fourth quarter valued at approximately $61,000. Woodline Partners LP lifted its stake in TScan Therapeutics by 6.7% during the 4th quarter. Woodline Partners LP now owns 115,866 shares of the company’s stock valued at $352,000 after acquiring an additional 7,282 shares in the last quarter. Squarepoint Ops LLC purchased a new position in TScan Therapeutics during the 4th quarter worth $59,000. Tang Capital Management LLC bought a new stake in shares of TScan Therapeutics in the 4th quarter worth $358,000. Finally, Shay Capital LLC purchased a new stake in shares of TScan Therapeutics in the fourth quarter valued at about $65,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

About TScan Therapeutics

(Get Free Report)

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.

Featured Articles

Earnings History and Estimates for TScan Therapeutics (NASDAQ:TCRX)

Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.